Dyax - Advancing Novel Biotherapeutics

Dedicated to finding new solutions for patients in need.

Home>Investors>Investor Overview

Investor Overview

Webcast ImageWebcast
Q2 2010 Dyax Corp. Earnings Conference Call (Replay)
Jul 28, 2010 at 10:00 a.m. ET
Profile

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with o... 

More >>

Stock QuoteMore >>
DYAX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.48
Change (%) Stock is Down 0.05 (1.98%)
Volume537,448
Data as of Jul 28, 2010 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
Jul 28, 2010Dyax Corp. Announces Second Quarter 2010 Financial Results
Quarter Highlighted By 266% Increase in KALBITOR(R) (ecallantide) Patients- CAMBRIDGE, Mass., Jul 28, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the second quarter ended June 30, 2010. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter. Patients currently in KALBITOR AccessSM program expanded to 264 HAE patients with KALBITOR(R) (ecallantide) at th... 
Printer Friendly Version
Jul 21, 2010Dyax Corp. to Host Second Quarter 2010 Earnings Call and Webcast
CAMBRIDGE, Mass., Jul 21, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, July 28, 2010, to discuss its financial results and company progress for the second quarter ended June 30, 2010. Date: Wednesday, July 28, 2010 Time: 10:00 a.m. ET Telephone Access: Domestic callers, dial 800-561-2601 International callers, dial 617-... 
Printer Friendly Version
Jul 19, 2010Dyax Features Comprehensive Financial Assistance Program On Enhanced Product Website for KALBITOR(R) (ecallantide)
CAMBRIDGE, Mass., Jul 19, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) today announced that it has launched its newly enhanced product website, http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.KALBITOR.com&esheet=6363207&lan=en-US&anchor=www.KALBITOR.com&index=3&md5=daf9eacd6f4f7439a22b3620141c703c, featuring its comprehensive financial assistance program. KALBITOR(R) (ecallantide) is approved for the treatment of acute attacks of hereditary angioe... 
Printer Friendly Version
Jul 6, 2010Dyax Announces Marketing Authorization Application for DX-88 (ecallantide) Validated by European Medicines Agency
CAMBRIDGE, Mass., Jul 06, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ: DYAX) announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU). The completion of this validation process signifies that the formal scientific review of the MAA has begun. DX-88 (ecallantide) has been approved by the U.S. Food and Drug Administration (FDA) and i... 
Printer Friendly Version
Calendar of EventsMore >>
There are currently no events scheduled.
Event ArchivesMore >>
DateTitle
Jul 28, 2010
Download Documentation Q2 2010 Dyax Corp. Earnings Conference Call
Apr 28, 2010
Download Documentation Q1 2010 Dyax Corp. Earnings Conference Call
Feb 17, 2010
Download Documentation Q4 2009 Dyax Corp. Earnings Conference Call
Get help downloading or viewing the above file types
Featured Financial ReportsMore >>
Filing DateForm
May 3, 201010-Q Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
Apr 15, 2010
2009 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Stock quote

ExchangeNASDAQ (US Dollar)
Price$2.48
Change (%) Stock is Down 0.05 (1.98%)
See more

IR Tool Kit

E-mail Alerts  E-mail Alerts
IR Contacts  IR Contacts
RSS Feeds  RSS Feeds
Investor Kit  Online Investor Kit

Investor Relations Contacts

Ivana Magovcevic-Liebisch
Executive Vice President Corporate Development and General Counsel
Dyax Corp.
Phone: 617-225-2500


Nicole Jones
Director, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500

See All